Catalytic microgelators for decoupled control of gelation rate and rigidity of biological gels
View Patent ↗Provided herein are stimulus-responsive polymer microgelator particles that can activate fibrin fiber formation from their surfaces by actively ejecting thrombin to form an interconnected fibrin network with an increased elastic modulus and desirable microstructure. The use of the microgelators enables the decoupling of gelation rate and gel rigidity.
1. A composition comprising a core containing a (i) catalyst for decomposition of hydrogen peroxide (H 2 O 2 ) and (ii) thrombin, wherein the catalyst for the decomposition of hydrogen peroxide is manganese oxide (MnO 2 ) particles or nanosheets, platinum (Pt), CuO (copper II oxide) particles or nanosheets, zinc peroxide (ZnO 2 ) particles or nanosheets, or catalase, and a polymer shell, wherein the catalyst for the decomposition of hydrogen peroxide (H 2 O 2 ) and thrombin are located within the polymer shell.
2. The composition of claim 1 , wherein the composition is lyophilized.
3. The composition of claim 1 , wherein the polymer is a biodegradable polymer.
4. The composition of claim 1 , wherein 1 mg of the composition comprises about 1 μg to about 20 μg of catalyst for the decomposition of H 2 O 2 and about 25 ng to about 150 ng of thrombin.
5. A method of clotting blood or a blood product containing fibrinogen comprising:
(a) adding H 2 O 2 to the composition of claim 1 to form a mixture and adding the mixture to the blood or blood product;
(b) adding H 2 O 2 to the blood or blood product to form a mixture and adding the composition of claim 1 to the mixture; or
(c) adding H 2 O 2 and the composition of claim 1 to the blood or blood product to form a mixture.
6. The method of claim 5 , wherein fibrinogen is additionally added to the blood or blood product or to any of the mixtures of (a), (b), or (c).
7. A method of promoting blood clotting in a subject comprising adding H 2 O 2 to the composition of claim 1 to form a mixture and then administering an effective amount of the mixture to the subject.
8. The method of claim 7 , wherein fibrinogen is added to the mixture before administering the mixture to the subject.
9. The method of claim 7 , wherein the subject has a coagulopathic condition or tissue defect and the method is effective for treating the coagulopathic condition or tissue defect in the subject.
10. The method of claim 9 , wherein the tissue defect is an external wound, an internal wound, an ulcer, a burn, a natural defect, a surgical incision, or any combination thereof.
11. The method of claim 9 , wherein the tissue defect is caused by traumatic injury, disease, infection, surgical intervention, natural causes, or any combinations thereof.
12. A method of making a gel comprising contacting the composition of claim 1 with a fibrinogen solution or powder and H 2 O 2 to form a mixture and allowing the mixture to form a gel.
13. The method of claim 12 , wherein the fibrinogen is present at about 0.5 mg/ml to about 5.0 mg/ml in the fibrinogen solution or mixture and the H 2 O 2 is present at about 0.1 mM to about 0.6 mM.
14. The method of claim 12 , further comprising adding one or more types of cells to the mixture so that the cells are present within the gel.
15. The method of claim 14 , wherein the one or more types of cells are endothelial cells, fibroblast cells, tissue specific cells, or a combination thereof.
16. The method of claim 15 , wherein the endothelial cells are adult vein endothelial cells, adult artery endothelial cells, embryonic stem cell-derived endothelial cells, iPS-derived endothelial cells, umbilical vein endothelial cells, umbilical artery endothelial cells, endothelial progenitor cells derived from bone marrow, endothelial progenitor cells derived from cord blood, endothelial progenitor cells derived from peripheral blood, endothelial progenitor cells derived from adipose tissues, or combinations thereof.
17. The method of claim 16 , wherein the umbilical vein endothelial cells are human umbilical vein endothelial cells (HUVEC).
18. The method of claim 15 , wherein the fibroblast cells are human foreskin fibroblasts, human embryonic fibroblasts, mouse embryonic fibroblasts, skin fibroblast cells, vascular fibroblast cells, myofibroblasts, smooth muscle cells, mesenchymal stem cells (MSCs)-derived fibroblast cells, or combinations thereof.
19. The method of claim 15 , wherein the tissue-specific cells are muscle cells, pancreatic beta cells, osteoblasts, chondrocytes, myoblasts, adipocytes, neuronal cells, glial cells, cardiomyocytes, liver cells, urethral cells, kidney cells, periosteal cells, bladder cells, odontoblasts, dental pulp cells, periodontal cells, tenocytes, lung cells, cardiac cells, skeletal cells, stem cell, iPS cell derived tissue specific cells, or a combination thereof.
20. The method of claim 15 , wherein the tissue specific cells are myoblasts, pancreatic beta-islet cells, cardiomyocytes, liver cells, lung cells, neural cells, bone cells, kidney cells, or combinations thereof.
21. A method of making catalytic microgelator particles comprising:
(a) adding thrombin to a suspension of an H 2 O 2 decomposition catalyst to form an internal aqueous phase mixture;
(b) adding the internal aqueous phase mixture to an organic phase comprising a polymer in a solvent and mixing to form a first emulsion;
(c) adding the first emulsion to an external aqueous phase solution comprising a water soluble polymer and mixing to prepare a second emulsion; and
(d) collecting the resulting catalytic microgelator particles, which comprise a core containing the thrombin and the H 2 O 2 decomposition catalyst located within a polymer shell.
22. A method of clotting blood or a blood product comprising adding the composition of claim 1 to the blood or blood product.